Skip to content
DataLookout
Menu

NCT07459634

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 6 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jan 31, 2028 to Aug 4, 2029 Show 4 more changesShow less
    • Study completion pushed from Apr 30, 2028 to Nov 4, 2029
    • Start date changed from estimate of Nov 30, 2026 to Oct 12, 2026
    • Study sites: 5 to 6
    • Secondary endpoints: 5 to 6
  2. Notable Eligibility criteria expanded, about 17 words
    • Study sites: 4 to 5
  3. Notable Start date: Aug 30, 2026 to Nov 30, 2026
    • Eligibility criteria shortened, about 7 words
    • Study description expanded, about 6 words
    v5
  4. Notable Recruitment opened
    • Start date: Jun 12, 2026 to Aug 30, 2026
    • Trial sites expanded: 1 → 4 locations
    v4
  5. Notable Start date: Apr 25, 2026 to Jun 12, 2026v3
  6. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Investigator assessed PFS rate
Timeframe: 6 months

Secondary (6)

Investigator assessed PFS
Investigator-assessed confirmed ORR
Number of participants requiring dose modification
Number of participants requiring discontinuations of any component of the combination therapy
Plasma Concentrations of lurbinectedin
Show 1 moreShow less
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

Arms and interventions

Durvalumab and lurbinectedin treatment armExperimental

Durvalumab taken in combination with lurbinectedin in participants with ES-SCLC after first line induction therapy with durvalumab and platinum plus etoposide containing regimen.

Drugs: Lurbinectedin, Durvalumab

Sites

6 sites in 1 country